BioTuesdays
Sutra-Biopharma-Logo
Markets

HCW starts Sutro Biopharma at buy; PT $35

H.C. Wainwright initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and price target of $35. The stock closed at $18.73 on June 17. “We believe Sutro Biopharma can continue to be a standout performer...

June 17, 2021
Metacrine
Markets

HCW starts Metacrine at buy; PT $15

H.C. Wainwright launched coverage of Metacrine (NASDAQ:MTCR) with a “buy” rating and $15 price target. The stock closed at $4.14 on June 11. Metacrine is a clinical-stage biopharmaceutical company focused on discovering...

June 14, 2021
RAPT-Therapeutics
Markets

Cantor ups RAPT Therapeutics PT to $71 from $51

Cantor Fitzgerald raised its price target for RAPT Therapeutics (NASDAQ:RAPT) to $71 from $51, citing an increased probability of success for RPT193 in atopic dermatitis to 50% from 25% previously, and taking up peak...

June 14, 2021
CareCloud
Markets

Cantor starts CareCloud at OW: PT $15

Cantor Fitzgerald launched coverage of CareCloud (NASDAQ:MTBC) with an “overweight” rating and $15 price target. The stock closed at $8.54 on June 10. CareCloud, formerly known as MTBC Inc., provides a broad range of...

June 11, 2021
myomo logo
Markets

AGP starts Myomo at buy; PT $36.50

Alliance Global Partners initiated coverage of Myomo (NYSEA:MYO) with a “buy” rating and price target of $36.50. The stock closed at $10.19 on June 9. “Myomo, in our view, represents one of the most compelling stories...

June 10, 2021
Unity-Biotechnology
Markets

HCW starts UNITY Biotechnology at buy; PT $12

H.C. Wainwright launched coverage of UNITY Biotechnology (NASDAQ:UBX) with a “buy” rating and $12 price target. The stock closed at $4.56 on June 4. UNITY is focusing on therapeutics addressing diseases of aging, while...

June 7, 2021
PDS Biotechnology Logo
Markets

HCW ups PDS Biotechnology PT to $20 from $8

H.C. Wainwright raised its price target for PDS Biotechnology (NASDAQ:PDSB) to $20 from $8 ahead of additional data being released at the ASCO meeting this weekend. The stock closed at $10.86 on June 1. “We believe that...

June 2, 2021
Cutera
Markets

Cantor starts Cutera at OW; PT $55

Cantor Fitzgerald initiated coverage of Cutera (NASDAQ:CUTR) with an “overweight” rating and 12-month price target of $55. The stock closed at $40.86 on June 1. “Cutera’s comprehensive portfolio of innovative aesthetic...

June 2, 2021
Seelos Therapeutics Logo
Markets

Cantor starts Seelos Therapeutics at OW; PT $10

Cantor Fitzgerald launched coverage of Seelos Therapeutics (NASDAQ:SEEL) with an “overweight” rating and 12-to-18 month price target of $10. The stock closed at $3.08 on May 28. Analyst Charles Duncan, Ph.D., writes...

June 1, 2021
Harpoon Therapeutics
Markets

Cantor starts Harpoon Therapeutics at OW; PT $40

Cantor Fitzgerald initiated coverage of Harpoon Therapeutics (NASDAQ:HARP) with an “overweight” rating and $40 price target. The stock closed at $20.28 on May 27. Harpoon is an immunoncology company developing a next...

May 28, 2021
Corvus Pharmaceuticals
Markets

Cantor starts Corvus Pharma at OW; PT $10

Cantor Fitzgerald launched coverage of Corvus Pharmaceuticals (NASDAQ:CRVS) with an “overweight” rating and 12-month price target of $10. The stock closed at $2.66 on May 26. “We believe that the risk/reward profile is...

May 27, 2021
Chemomab-Therapeutics
Markets

Cantor starts Chemomab Therapeutics at OW; PT $45

Cantor Fitzgerald initiated coverage of Chemomab Therapeutics (NASDAQ:CMMB) with an “overweight” rating and $45 price target. The stock closed at $16.07 on May 25. Chemomab is a clinical-stage biotech company focusing...

May 26, 2021
Asensus-Surgical
Markets

HCW starts Asensus Surgical at buy; PT $4

H.C. Wainwright launched coverage of Asensus Surgical (NYSE American:ASXC) with a “buy” rating and price target of $4. The stock closed at $2.03 on May 25. Asensus, a surgical robotics company, is digitizing laparoscopy...

May 26, 2021
Vaccitech
Markets

WB starts Vaccitech at OP

William Blair initiated coverage of Vaccitech plc (NASDAQ:VACC) with an “outperform” rating. The stock was quoted at $14.35 in afternoon trading on May 25. Vaccitech is a clinical-stage biotechnology company that...

May 25, 2021
Verastem
Markets

BTIG ups Verastem to buy from neutral; PT $8

BTIG upgraded Verastem (NASDAQ:VSTM) to “buy” from “neutral” with a new price target of $8, citing a breakthrough designation from the FDA for its KRAS-focused combination therapy of VS-6766 with defactinib for all...

May 24, 2021
Clene-Nanomedicine
Markets

Maxim starts Clene at buy; PT $18

Maxim Group launched coverage of Clene (NASDAQ:CLNN) with a “buy” rating and $18 price target. The stock closed at $8.95 on May 19. Clene is a clinical-stage company developing CNM-Au8, an oral, clean-surfaced faceted...

May 20, 2021
Neuropace
Markets

SVB Leerink starts NeuroPace at OP; PT $25

SVB Leerink initiated coverage of Neuropace (NASDAQ:NPCE) with an “outperform” rating and $25 price target. The stock closed at $20.91 on May 14. “To us, NeuroPace represents a top-tier growth profile SMID-cap MedTech...

May 17, 2021
Dyadic
Markets

Dawson James halves Dyadic PT to $6 from $12

Dawson James reduced its price target for Dyadic (NASDAQ:DYAI) to $6 from $12, citing uncertainty about the potential of its COVID-19 vaccine. The stock closed at $3.73 on May 14. “DYAI-100 (COVID) is advancing to human...

May 17, 2021
Annovis Logo
Markets

Maxim ups Annovis Bio PT to $45 from $12

Maxim Group raised its price target for Annovis Bio (NYSE American: ANVS) to $45 from $12, citing upcoming Phase 2a data evaluating ANVS401 in Alzheimer’s disease (AD) and Parkinson’s disease (PD) patients. The stock...

May 13, 2021
4D-Pharma-PLC
Markets

Ladenburg starts 4D Pharma at buy; PT $35

Ladenburg Thalmann launched coverage of 4D Pharma PLC (NASDAQ:LBPS) with a “buy” rating and $35 price target. The stock closed at $10.55 on May 12. 4D Pharma is a Leeds, UK-based biotechnology company developing live...

May 13, 2021